Cindy Cole
Partner @ Digitalis Ventures
New York, United States
Cindy Cole is a Series B investor at Digitalis Ventures in New York focused on Biotechnology and Pet. Dr. Cynthia Cole serves as a Partner at Digitalis Ventures. She received her DVM and Ph.D. in cardiovascular pharmacology from the University of Florida. She has served on the faculty of UC Davis and is currently an Associate Clinical Professor and Director of the Racing Laboratory at the University of Florida. Cindy is also a diplomate of theAmerican College of Veterinary Clinical Pharmacology. Prior to joining Digitals, she held R&D and management roles with IDEXX, Novartis Animal Health, Piedmont Pharmaceuticals and Mars Petcare.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 69%
Last updated:
For AI agents: llms.txt
Industries Cindy Cole invests in
Stages Cindy Cole invests in
Countries Cindy Cole invests in
Investment Focus
Industry
- Biotechnology 4 (31%)
- Pet 3 (23%)
- Veterinary 3 (23%)
- Health Care 3 (23%)
- Therapeutics 2 (15%)
Stage
- Series B 5 (38%)
- Series A 4 (31%)
- Seed 2 (15%)
Country
- United States 6 (46%)
- Australia 1 (8%)
- United Kingdom 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Travv
|
Travv is a startup focused on veterinary diagnostics powered by AI. It offers cloud-based services connecting veterinarians worldwide with expert diagnosticians for streamlined workflows in areas like radiology, pathology, and cardiology. | $1.6M / Seed / May 06, 2026 | |
Gallant Therapeutics
|
Gallant Therapeutics is an animal health biotechnology company developing allogeneic, "off-the-shelf" stem cell therapies from their stem cell platform. Gallant is also the leading provider of non-invasive stem cell banking during the spay or neuter process, opening the door to novel regenerative medical treatments formerly unavailablefor non-human family members. Clinical studies demonstrate stem cell therapies help pets with a multitude of ailments, including osteoarthritis, atopic dermatitis, chronic kidney disease, and chronic stomatitis, among others. Gallant's first product helps to save cats that would die of chronic gingivostomatitis, with a robust pipeline in development for companion animals. | Series B / Jun 30, 2025 | |
Gallant
|
Gallant is developing a scalable stem cell therapy platform that will allow any veterinarian to routinely treat pets in a primary care setting, improving the lives of pets and their people. By systematically addressing challenges that previously hindered stem cell therapy adoption, the company aims to make stem cell products accessible in order toelevate the quality of life for all pets and the people that love them. | $18M / Series B / Mar 15, 2025 | |
|
Gallant Therapeutics
|
Gallant Therapeutics is an animal health biotechnology company developing allogeneic, "off-the-shelf" stem cell therapies from their stem cell platform. Gallant is also the leading provider of non-invasive stem cell banking during the spay or neuter process, opening the door to novel regenerative medical treatments formerly unavailablefor non-human family members. Clinical studies demonstrate stem cell therapies help pets with a multitude of ailments, including osteoarthritis, atopic dermatitis, chronic kidney disease, and chronic stomatitis, among others. Gallant's first product helps to save cats that would die of chronic gingivostomatitis, with a robust pipeline in development for companion animals. | $15M / Series A / Jan 08, 2024 | |
|
Gallant
|
Gallant is developing a scalable stem cell therapy platform that will allow any veterinarian to routinely treat pets in a primary care setting, improving the lives of pets and their people. By systematically addressing challenges that previously hindered stem cell therapy adoption, the company aims to make stem cell products accessible in order toelevate the quality of life for all pets and the people that love them. | Series A / Jan 08, 2024 | |
|
Gallant
|
Gallant is developing a scalable stem cell therapy platform that will allow any veterinarian to routinely treat pets in a primary care setting, improving the lives of pets and their people. By systematically addressing challenges that previously hindered stem cell therapy adoption, the company aims to make stem cell products accessible in order toelevate the quality of life for all pets and the people that love them. | $15M / Series A / Jan 08, 2024 | |
Smalls
|
Smalls is a direct-to-consumer pet food company that produces human-grade and fresh food for cats.The company's cat food is prepared with human-grade ingredients and offers customized kits as per the cat's nutrition needs, enabling pet owners to get healthy and fresh food directly at their doorstep. It offers variants such as chickenand beef; freeze-dried chicken, and turkey and duck.In 2017, co-founders and best friends Matt Michaelson and Calvin headquartered the company in New York, New York. | $19M / Series B / Mar 28, 2023 | |
Vedi
|
Smarter, connected veterinary care. Vedi is building a better future for vets and pets through trusted dataVeterinary care today is disconnected, manual, often paper-based and putting unneeded stress on overworked vets.Vedi is building the future of animal care – a digital veterinary system connected by trustworthy health data.In the vetpractice, vets use Vedi to do more in less time – submit and track pathology work, register a microchip, manage vaccinations and more at the touch of a button.Outside of the practice, Vedi is improving and connecting the whole system – and providing true continuity of care.Vedi locks verified, error-free health data to an animal’s microchip. That means wherever it goes – a new state, a shelter or the emergency room – anyone treating that animal can access its vital health information. | $3M / Seed / Jan 13, 2023 | |
MySimplePetLab
|
MySimplePetLab is a distributed pet care testing and results. It provides the tests, technology, lab, operations, and results to deliver simple pet care from home and/or in the clinic. Founded in 2019, the company is based in Centennial, Colorado, United States. | $5M / Series A / Oct 06, 2022 | |
Scout Bio
|
Scout Bio is a biotechnology company that specializes in veterinary, animal health, and gene therapy. The company is driven by its mission is to harness the genetic revolution transforming human medicine to deliver the future of veterinary medicine. Scout Bio was founded in 2016 and headquartered in Pennsylvania, United States. | $33M / Series B / Oct 19, 2021 | |
| See all 13 investments → | |||
Co-Investors
About Digitalis Ventures
Digitalis is a venture capital firm that that invests in solutions to complex problems in human and animal health. Digitalis partners with entrepreneurs, inventors, and scientists across all stages of venture investing, and our investments span the full continuum of the healthcare ecosystem. It was founded in 2016 and is Headquartered in New York,New York with regional offices in Boston, Los Angeles, and San Francisco.
Digitalis Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Amit Bansal
Partner
|
|||
|
Cindy Cole
Partner
|
|||
Dac Nguye
Technical Partner
|
|||
Drew Taylor
Partner
|
|||
Geoffrey W. Smith
founder and managing partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Cindy Cole invest in?
Cindy Cole invests primarily in Biotechnology, Pet and Veterinary startups, most often at Series B and Series A stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Cindy Cole last invest?
The most recent investment recorded for Cindy Cole closed in May 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
